FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:543-551 August 5, 2004 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by McMurray, J. J.V. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The Randomized Aldactone Evaluation Study (RALES) demonstrated that spironolactone significantly improves outcomes in patients with severe heart failure. Use of angiotensin-converting–enzyme (ACE) inhibitors is also indicated in these patients. However, life-threatening hyperkalemia can occur when these drugs are used together.

Methods We conducted a population-based time-series analysis to examine trends in the rate of spironolactone prescriptions and the rate of hospitalization for hyperkalemia in ambulatory patients before and after the publication of RALES. We linked prescription-claims data and hospital-admission records for more than 1.3 million adults 66 years of age or older in Ontario, Canada, for the period from 1994 through 2001.

Results Among patients treated with ACE inhibitors who had recently been hospitalized for heart failure, the spironolactone-prescription rate was 34 per 1000 patients in 1994, and it increased immediately after the publication of RALES, to 149 per 1000 patients by late 2001 (P<0.001). The rate of hospitalization for hyperkalemia rose from 2.4 per 1000 patients in 1994 to 11.0 per 1000 patients in 2001 (P<0.001), and the associated mortality rose from 0.3 per 1000 to 2.0 per 1000 patients (P<0.001). As compared with expected numbers of events, there were 560 (95 percent confidence interval, 285 to 754) additional hyperkalemia-related hospitalizations and 73 (95 percent confidence interval, 27 to 120) additional hospital deaths during 2001 among older patients with heart failure who were treated with ACE inhibitors in Ontario. Publication of RALES was not associated with significant decreases in the rates of readmission for heart failure or death from all causes.

Conclusions The publication of RALES was associated with abrupt increases in the rate of prescriptions for spironolactone and in hyperkalemia-associated morbidity and mortality. Closer laboratory monitoring and more judicious use of spironolactone may reduce the occurrence of this complication.

Source Information

From the Departments of Medicine (D.N.J., D.S.L., A.L., D.A.R.), Pharmacy (M.M.M.), Health Policy, Management, and Evaluation (D.N.J., M.M.M., D.S.L., P.C.A., A.L., D.A.R.), and Public Health Sciences (P.C.A.), University of Toronto; and the Institute for Clinical Evaluative Sciences (D.N.J., M.M.M., D.S.L., A.K., P.C.A., A.L., D.A.R.) — both in Toronto.

Address reprint requests to Dr. Juurlink at Sunnybrook and Women's College Health Sciences Centre, G Wing 106, 2075 Bayview Ave., Toronto, ON M4N 3M5, Canada, or at dnj{at}ices.on.ca.

Full Text of this Article

Related Letters:

Hyperkalemia after the Publication of RALES
Goldfarb D. S., Newsome B. B., Warnock D. G., Witham M. D., Gillespie N. D., Struthers A. D., Cavallari L., Vaitkus P., Groo V., Juurlink D. N., Mamdani M. M., Redelmeier D. A.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:2448-2450, Dec 2, 2004. Correspondence

This article has been cited by other articles:

• Krumholz, H. M. (2008). Outcomes Research: Generating Evidence for Best Practice and Policies. Circulation 118: 309-318 [Full Text]  
• Henz, S., Maeder, M. T., Huber, S., Schmid, M., Loher, M., Fehr, T. (2008). Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 0: gfn380v1-gfn380 [Abstract] [Full Text]  
• Ruggenenti, P., Perticucci, E., Cravedi, P., Gambara, V., Costantini, M., Sharma, S. K., Perna, A., Remuzzi, G. (2008). Role of Remission Clinics in the Longitudinal Treatment of CKD. J. Am. Soc. Nephrol. 19: 1213-1224 [Full Text]  
• Stevenson, L. W. (2008). Challenges for the Basis of Practice in Heart Failure. Circ Heart Fail 1: 81-83 [Abstract] [Full Text]  
• Tobin, M. J. (2008). Counterpoint: Evidence-Based Medicine Lacks a Sound Scientific Base. Chest 133: 1071-1074 [Full Text]  
• Mamdani, M., Ching, A., Golden, B., Melo, M., Menzefricke, U. (2008). Challenges to Evidence-Based Prescribing in Clinical Practice. The Annals of Pharmacotherapy 42: 704-707 [Abstract] [Full Text]  
• Levi, M., Hovingh, G. K., Cannegieter, S. C., Vermeulen, M., Buller, H. R., Rosendaal, F. R. (2008). Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 111: 4471-4476 [Abstract] [Full Text]  
• Connell, J. M. C., MacKenzie, S. M., Freel, E. M., Fraser, R., Davies, E. (2008). A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function. Endocr. Rev. 29: 133-154 [Abstract] [Full Text]  
• Garg, A. X., Greene, T., Levin, N. W. (2008). A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. Nephrol Dial Transplant 23: 52-55 [Full Text]  
• Kunz, R., Friedrich, C., Wolbers, M., Mann, J. F.E. (2008). Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. ANN INTERN MED 148: 30-48 [Abstract] [Full Text]  
• Parfrey, P. S. (2008). Inhibitors of the Renin-Angiotensin System: Proven Benefits, Unproven Safety. ANN INTERN MED 148: 76-77 [Full Text]  
• Zheng, D., Perianayagam, A., Lee, D. H., Brannan, M. D., Yang, L. E., Tellalian, D., Chen, P., Lemieux, K., Marette, A., Youn, J. H., McDonough, A. A. (2008). AMPK activation with AICAR provokes an acute fall in plasma [K+]. Am. J. Physiol. Cell Physiol. 294: C126-C135 [Abstract] [Full Text]  
• Moore, C., Lin, J., McGinn, T., Halm, E. (2007). Factors Associated with Time to Follow-up of Severe Hyperkalemia in the Ambulatory Setting. American Journal of Medical Quality 22: 428-437 [Abstract]  
• Crop, M. J., Hoorn, E. J., Lindemans, J., Zietse, R. (2007). Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant 22: 3471-3477 [Abstract] [Full Text]  
• Juurlink, D. N. MD PhD, Park-Wyllie, L. Y. PharmD MSc, Kapral, M. K. MD MSc (2007). The effect of publication on Internet-based solicitation of personal-injury litigants. CMAJ 177: 1369-1370 [Abstract] [Full Text]  
• Desai, A. S., Swedberg, K., McMurray, J. J.V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., Michelson, E. L., Pfeffer, M. A., on behalf of the CHARM Program Investigators, (2007). Incidence and Predictors of Hyperkalemia in Patients With Heart Failure: An Analysis of the CHARM Program. J Am Coll Cardiol 50: 1959-1966 [Abstract] [Full Text]  
• Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Buch, P., Sorensen, R., Folke, F., Gadsboll, N., Rasmussen, S., Kober, L., Madsen, M., Torp-Pedersen, C. (2007). Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes. Circulation 116: 737-744 [Abstract] [Full Text]  
• Joffe, H. V., Kwong, R. Y., Gerhard-Herman, M. D., Rice, C., Feldman, K., Adler, G. K. (2007). Beneficial Effects of Eplerenone Versus Hydrochlorothiazide on Coronary Circulatory Function in Patients with Diabetes Mellitus. J. Clin. Endocrinol. Metab. 92: 2552-2558 [Abstract] [Full Text]  
• Pitt, B., Pitt, G. S. (2007). Added Benefit of Mineralocorticoid Receptor Blockade in the Primary Prevention of Sudden Cardiac Death. Circulation 115: 2976-2982 [Full Text]  
• Komajda, M., Hanon, O., Hochadel, M., Follath, F., Swedberg, K., Gitt, A., Cleland, J. G.F. (2007). Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J 28: 1310-1318 [Abstract] [Full Text]  
• Lang, C. C, Mancini, D. M (2007). Non-cardiac comorbidities in chronic heart failure. Heart 93: 665-671 [Abstract] [Full Text]  
• Kielstein, J. T., Woywodt, A., Salpeter, S. R. (2007). Letter by Kielstein et al Regarding Article, "High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid". Circulation 115: e450-e451 [Full Text]  
• Rowan, S. B., Bailey, D. N., Bublitz, C. E., Anderson, R. J. (2007). Trends in Anticoagulation for Atrial Fibrillation in the U.S.: An Analysis of the National Ambulatory Medical Care Survey Database. J Am Coll Cardiol 49: 1561-1565 [Abstract] [Full Text]  
• Kurdyak, P. A., Juurlink, D. N., Mamdani, M. M. (2007). The Effect of Antidepressant Warnings on Prescribing Trends in Ontario, Canada. Am. J. Public Health 97: 750-754 [Abstract] [Full Text]  
• Chapman, N., Dobson, J., Wilson, S., Dahlof, B., Sever, P. S., Wedel, H., Poulter, N. R., on behalf of the Anglo-Scandinavian Cardiac Outcom, (2007). Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension 49: 839-845 [Abstract] [Full Text]  
• Van Spall, H. G. C., Toren, A., Kiss, A., Fowler, R. A. (2007). Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical Journals: A Systematic Sampling Review. JAMA 297: 1233-1240 [Abstract] [Full Text]  
• Redelmeier, D. A., Bell, C. M. (2007). Weekend Worriers. NEJM 356: 1164-1165 [Full Text]  
• Maeder, M., Rickli, H., Sticherling, C., Widmer, R., Ammann, P. (2007). Hypokalaemia and sudden cardiac death--lessons from implantable cardioverter defibrillators. Emerg. Med. J. 24: 206-208 [Abstract] [Full Text]  
• Smellie, W S A, Forth, J, Coleman, J J, Irvine, W, Dore, P C, Handley, G, Williams, D G, Galloway, P J, Kerr, K G, Herriot, R, Spickett, G P, Reynolds, T M (2007). Best practice in primary care pathology: review 6. J. Clin. Pathol. 60: 225-234 [Abstract] [Full Text]  
• Raebel, M. A, McClure, D. L, Chan, K A., Simon, S. R, Feldstein, A. C, Lafata, J. E., Andrade, S. E, Gunter, M. J, Nelson, W. W, Roblin, D., Platt, R. (2007). Laboratory Evaluation of Potassium and Creatinine Among Ambulatory Patients Prescribed Spironolactone: Are We Monitoring for Hyperkalemia?. The Annals of Pharmacotherapy 41: 193-200 [Abstract] [Full Text]  
• Bubbar, C. D, Blackburn, D. F, Wilson, M. P, Wilson, T. W (2007). Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Hypertension Due to Primary Aldosteronism: A Case for Exclusion. The Annals of Pharmacotherapy 41: 129-132 [Abstract] [Full Text]  
• Martin, U., Coleman, J. J (2006). Monitoring renal function in hypertension.. BMJ 333: 896-899 [Full Text]  
• Hauptman, P. J., Schnitzler, M. A., Swindle, J., Burroughs, T. E. (2006). Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.. JAMA 296: 1877-1884 [Abstract] [Full Text]  
• Calhoun, D. A. (2006). Aldosteronism and Hypertension. CJASN 1: 1039-1045 [Abstract] [Full Text]  
• Groban, L., Butterworth, J. (2006). Perioperative management of chronic heart failure.. Anesth. Analg. 103: 557-575 [Abstract] [Full Text]  
• Howard, P. A, Cheng, J. W., Crouch, M. A, Colucci, V. J, Kalus, J. S, Spinler, S. A, Munger, M. (2006). Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure. The Annals of Pharmacotherapy 40: 1607-1616 [Abstract] [Full Text]  
• Verhamme, K., Mosis, G., Dieleman, J., Stricker, B., Sturkenboom, M. (2006). Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ 333: 330- [Abstract] [Full Text]  
• Austin, P. C, Mamdani, M. M, Juurlink, D. N (2006). How Many "Me-Too" Drugs Are Enough? The Case of Physician Preferences for Specific Statins. The Annals of Pharmacotherapy 40: 1047-1051 [Abstract] [Full Text]  
• Gheorghiade, M., van Veldhuisen, D. J., Colucci, W. S. (2006). Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation 113: 2556-2564 [Full Text]  
• Covic, A., Gusbeth-Tatomir, P., Goldsmith, D. J. A. (2006). Is it time for spironolactone therapy in dialysis patients?. Nephrol Dial Transplant 21: 854-858 [Full Text]  
• Brady, A J B, Poole-Wilson, P A (2006). ESC-CHF: guidelines for the aspirational and the practical.. Heart 92: 437-440 [Abstract] [Full Text]  
• Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., Mamdani, M. M. (2006). Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults. NEJM 354: 1352-1361 [Abstract] [Full Text]  
• Moore, C. R., Lin, J. J., O'Connor, N., Halm, E. A. (2006). Follow-up of Markedly Elevated Serum Potassium Results in the Ambulatory Setting: Implications for Patient Safety.. American Journal of Medical Quality 21: 115-124 [Abstract]  
• de Silva, R., Nikitin, N. P., Witte, K. K.A., Rigby, A. S., Goode, K., Bhandari, S., Clark, A. L., Cleland, J. G.F. (2006). Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 27: 569-581 [Abstract] [Full Text]  
• Kimmel, P. L. (2006). Update in nephrology and hypertension.. ANN INTERN MED 144: 281-285 [Full Text]  
• Lexchin, J. (2006). Is there still a role for spontaneous reporting of adverse drug reactions?. CMAJ 174: 191-192 [Full Text]  
• Schrier, R. W. (2006). Role of Diminished Renal Function in Cardiovascular Mortality: Marker or Pathogenetic Factor?. J Am Coll Cardiol 47: 1-8 [Abstract] [Full Text]  
• Ahmed, A., Rich, M. W., Love, T. E., Lloyd-Jones, D. M., Aban, I. B., Colucci, W. S., Adams, K. F., Gheorghiade, M. (2006). Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27: 178-186 [Abstract] [Full Text]  
• Marcy, T. R., Ripley, T. L. (2006). Aldosterone antagonists in the treatment of heart failure. Am J Health Syst Pharm 63: 49-58 [Abstract] [Full Text]  
• Lenzen, M. J., Boersma, E., Scholte op Reimer, W. J.M., Balk, A. H.M.M., Komajda, M., Swedberg, K., Follath, F., Jimenez-Navarro, M., Simoons, M. L., Cleland, J. G.F. (2005). Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 26: 2706-2713 [Abstract] [Full Text]  
• Fuller, P. J., Young, M. J. (2005). Mechanisms of Mineralocorticoid Action. Hypertension 46: 1227-1235 [Abstract] [Full Text]  
• Montori, V. M., Devereaux, P. J., Adhikari, N. K. J., Burns, K. E. A., Eggert, C. H., Briel, M., Lacchetti, C., Leung, T. W., Darling, E., Bryant, D. M., Bucher, H. C., Schunemann, H. J., Meade, M. O., Cook, D. J., Erwin, P. J., Sood, A., Sood, R., Lo, B., Thompson, C. A., Zhou, Q., Mills, E., Guyatt, G. H. (2005). Randomized Trials Stopped Early for Benefit: A Systematic Review. JAMA 294: 2203-2209 [Abstract] [Full Text]  
• Koch, E., Otarola, A., Kirschbaum, A. (2005). A landmark for popperian epidemiology: refutation of the randomised Aldactone evaluation study. J. Epidemiol. Community Health 59: 1000-1006 [Abstract] [Full Text]  
• Warnock, D. G., Rossier, B. C. (2005). Renal Sodium Handling: The Role of the Epithelial Sodium Channel. J. Am. Soc. Nephrol. 16: 3151-3153 [Full Text]  
• Redelmeier, D., Scales, D., Kopp, A. (2005). {beta} blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ 331: 932- [Abstract] [Full Text]  
• Fang, J. C. (2005). Angiotensin-Converting Enzyme Inhibitors or {beta}-Blockers in Heart Failure: Does It Matter Who Goes First?. Circulation 112: 2380-2382 [Full Text]  
• Krumholz, H. M. (2005). The Year in Epidemiology, Health Services, and Outcomes Research. J Am Coll Cardiol 46: 1362-1370 [Full Text]  
• Gil, P., Justo, S., Caramelo, C. (2005). Cardio-renal failure: an emerging clinical entity. Nephrol Dial Transplant 20: 1780-1783 [Full Text]  
• Warnock, D. G., Bell, P. D. (2005). Improvement of Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension. Hypertension 46: 469-470 [Full Text]  
• Austin, P. C., Mamdani, M. M. (2005). Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada. Circulation 112: 1296-1300 [Abstract] [Full Text]  
• Masoudi, F. A., Gross, C. P., Wang, Y., Rathore, S. S., Havranek, E. P., Foody, J. M., Krumholz, H. M. (2005). Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998-2001. Circulation 112: 39-47 [Abstract] [Full Text]  
• Krzyzanowska, M. K., Treacy, J., Maloney, B., Lavino, A., Jacobson, J. O. (2005). Development of a Patient Registry to Evaluate Hospital Admissions Related to Chemotherapy Toxicity in a Community Cancer Center. J Oncol Pract 1: 15-19 [Abstract] [Full Text]  
• Buck, M. L (2005). Clinical Experience with Spironolactone in Pediatrics. The Annals of Pharmacotherapy 39: 823-828 [Abstract] [Full Text]  
• Burger, P. C., Rocca, H. B.-L. (2005). Pharmacotherapy of Congestive Heart Failure in Elderly Patients. J CARDIOVASC PHARMACOL THER 10: 85-94 [Abstract]  
• McAlister, F. A., Majumdar, S. R., Blitz, S., Rowe, B. H., Romney, J., Marrie, T. J. (2005). The Relation Between Hyperglycemia and Outcomes in 2,471 Patients Admitted to the Hospital With Community-Acquired Pneumonia. Diabetes Care 28: 810-815 [Abstract] [Full Text]  
• Moran, A. E., Cooper, R. S., Fitzgibbons, T. P., Chow, A. Y., Bellin, E. Y., Eisenberger, A. B., Taylor, A. L., Cohn, J., Worcel, M. (2005). Isosorbide dinitrate and hydralazine in blacks with heart failure.. NEJM 352: 1041-1043 [Full Text]  
• Yan, A. T., Yan, R. T., Liu, P. P. (2005). Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. ANN INTERN MED 142: 132-145 [Abstract] [Full Text]  
• Steinberg, E. P., Luce, B. R. (2005). Evidence Based? Caveat Emptor!. Health Aff (Millwood) 24: 80-92 [Abstract] [Full Text]  
• Barnes, B. J, Howard, P. A (2005). Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure. The Annals of Pharmacotherapy 39: 68-76 [Abstract] [Full Text]  
• (2004). Spironolactone Use in Practice: Risk for Hyperkalemia?. Journal Watch Cardiology 2004: 4-4 [Full Text]  
• Shumak, S. L., Redelmeier, D. A. (2004). How to read clinical journals: XII. How you too can profit from pharmaceutical advertisements. CMAJ 171: 1455-1456 [Full Text]  
• Goldfarb, D. S., Newsome, B. B., Warnock, D. G., Witham, M. D., Gillespie, N. D., Struthers, A. D., Cavallari, L., Vaitkus, P., Groo, V., Juurlink, D. N., Mamdani, M. M., Redelmeier, D. A. (2004). Hyperkalemia after the Publication of RALES. NEJM 351: 2448-2450 [Full Text]  
• Segal, A., Palmer, B. F. (2004). Hyperkalemia and Inhibitors of the Renin-Angiotensin-Aldosterone System. NEJM 351: 2450-2451 [Full Text]  
• (2004). Hyperkalemia Associated with Increased Prescribing of Spironolactone. JWatch Gastroenterology 2004: 9-9 [Full Text]  
• (2004). Spironolactone Use in Practice: Risk for Hyperkalemia?. Journal Watch Cardiology 2004: 1-1 [Full Text]  
• (2004). Hyperkalemia Associated with Increased Prescribing of Spironolactone. JWatch General 2004: 3-3 [Full Text]  
• Palmer, B. F. (2004). Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System. NEJM 351: 585-592 [Full Text]